# The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)

> **NCT00768066** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Miami** · enrollment: 65 (actual)

## Conditions studied

- Stem Cell Transplantation
- Ventricular Dysfunction, Left

## Interventions

- **BIOLOGICAL:** Autologous human mesenchymal cells (hMSCs)
- **BIOLOGICAL:** Autologous human bone marrow cells (hBMCs)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00768066
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2012-08
- **Final completion:** 2013-09
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2015-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00768066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00768066, "The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00768066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*